Most treatments target seizure reduction but do not adequately address the non-seizure-related symptoms of Dravet syndrome, such as cognitive impairment, developmental delays, and behavioral issues .

This potential one-time treatment approach aims to consistently and durably restore UBE3A expression and address the spectrum of symptoms ... ETX101 for Dravet syndrome, which targets the ...

Encoded Therapeutics Inc., a clinical-stage biotechnology company developing genetic medicines for severe central nervous system (CNS) disorders, announced today that it will present new preclinical ...

Phase 3 epilepsy program advancing with X-TOLE2 topline FOS data anticipated in H2 2025– Long-term azetukalner results from X-TOLE open-label ...

Harmony Biosciences surpassed $2 billion in cumulative net product revenue less than 5 years on the market, highlighting ...

The drug is specially formulated to relieve symptoms but does not produce ... There is a need for new treatments for LGS and Dravet syndrome: both are serious and often resistant to the drugs ...

Pre-clinical data suggests that targeting Nav1.1 could potentially address the underlying cause and symptoms of Dravet Syndrome. Xenon continues to attract top talent with extensive biopharmaceutical ...

Dravet syndrome (DS) is a severe form of epilepsy that includes symptoms such as: The first time anyone has a seizure (of any type) the healthcare provider should be notified immediately and ...

Broad-spectrum AEDs often treat generalized seizures, which have symptoms more commonly associated with ... used to treat seizures associated with Lennox-Gaustat syndrome (LGS) or Dravet syndrome in ...

Nausea. Severe abdominal pain. Compulsive bathing. These are some of the hallmarks of cannabinoid hyperemesis syndrome, a ...